We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current IX1 market cap is 31.85B. The company's latest EPS is USD 10.9171 and P/E is 39.08.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.71B | 3.22B | 3.37B | 3.66B | 3.9B |
| Operating Income | 694.52M | 932.03M | 898.77M | 1.1B | 1.13B |
| Net Income | 581.78M | 744.85M | 679.09M | 845.04M | 887.87M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.29B | 2.44B | 2.75B | 3.26B | 3.29B |
| Total Liabilities | 1.66B | 1.75B | 2.14B | 1.78B | 1.7B |
| Total Equity | 632.8M | 689.99M | 608.74M | 1.48B | 1.6B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 648.06M | 755.55M | 542.98M | 906.51M | 929M |
| Investing | -109.38M | -292.97M | -195.35M | -125.25M | -207.06M |
| Financing | -248.42M | -697.41M | -370.94M | -442M | -878.07M |
| Market Cap | 31.85B |
| Price to Earnings Ratio | 39.08 |
| Price to Sales Ratio | 8.9 |
| Price to Cash Ratio | 120.38 |
| Price to Book Ratio | 21.75 |
| Dividend Yield | - |
| Shares Outstanding | 81.33M |
| Average Volume (1 week) | 81 |
| Average Volume (1 Month) | 87 |
| 52 Week Change | -21.66% |
| 52 Week High | 506.80 |
| 52 Week Low | 373.60 |
| Spread (Intraday) | 3.4 (0.86%) |
| Company Name | Idexx Laboratories Inc |
| Address |
corporation trust center 1209 wilmington, delaware 19801 |
| Website | https://www.idexx.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
